Drug intelligence / Profile preview

HRS7415

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS7415 is an orally administered small molecule drug under development for the treatment of advanced malignant tumors, including solid tumors and breast cancer. It acts as an inhibitor of Akt (also known as protein kinase B or PKB), a serine/threonine kinase involved in regulating cell proliferation and survival. By inhibiting Akt, HRS7415 disrupts downstream signaling pathways critical for tumor growth and exerts anti-tumor effects. The drug is being developed by Jiangsu Hengrui Pharmaceuticals and has reached phase 1 clinical trials targeting patients with advanced cancers[1][2][3][4][7].

Targets

AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on HRS7415.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS7415.

Explore the full profile